PPGSU EFdA LNG Implant
- User: Female
- Hormonal: Hormonal
-
Delivery type:
- Subdermal
-
Intended Duration:
- Long-Acting
- Development Stage: Discovery & Early Development
- Developer(s)/researcher(s): Secant Group
Details
- API: Not Yet Determined - Tested with LNG and EFdA
- Target: Not Yet Determined
-
Mechanism of Action:
- Not Yet Determined
- Inactive Materials: PGSU
- Regimen: Not Yet Determined
- MPT: Potential MPT
- Promising Attributes: To be established - concept is in early development
Product Status
Active Early Development
History
In 2023, Secant Group, a medical textiles company, published a proof-of-concept that PGSU could be used as the delivery system for anti-HIV and contraceptive drugs in the form of a bioresorbable implants.